Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ACB
stocks logo

ACB

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax
Wall Street analysts forecast ACB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACB is 4.28 USD with a low forecast of 4.28 USD and a high forecast of 4.28 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast ACB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACB is 4.28 USD with a low forecast of 4.28 USD and a high forecast of 4.28 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
0 Sell
Hold
Current: 4.570
sliders
Low
4.28
Averages
4.28
High
4.28
Current: 4.570
sliders
Low
4.28
Averages
4.28
High
4.28
no data image
No Data

Valuation Metrics

The current forward P/E ratio for Aurora Cannabis Inc (ACB.O) is -23.61, compared to its 5-year average forward P/E of -56.13. For a more detailed relative valuation and DCF analysis to assess Aurora Cannabis Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-56.13
Current PE
-23.61
Overvalued PE
296.62
Undervalued PE
-408.88

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-40.08
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
211.69
Undervalued EV/EBITDA
-291.85

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.01
Current PS
0.00
Overvalued PS
5.81
Undervalued PS
0.22
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

ACB News & Events

Events Timeline

(ET)
2025-12-02
07:11:00
Aurora Cannabis Partners with Leafio to Expand Medical Cannabis Access in Australia
select
2025-11-05 (ET)
2025-11-05
07:11:21
Aurora Cannabis announces Q2 revenue of C$90.37M, up from C$81.12M a year ago.
select
2025-09-29 (ET)
2025-09-29
09:01:25
Video: Merus Soars Following Acquisition Agreement, MoonLake Declines After Trial Results
select
link
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.5
12-02PRnewswire
Aurora Cannabis Partners with Leafio to Enhance Medical Cannabis Access in Australia
  • Partnership Formation: Aurora Cannabis's subsidiary MedReleaf Australia has entered a distribution partnership with Leafio, aiming to distribute premium medical cannabis products to over 4,000 pharmacies through Leafio's nationwide supply chain, significantly enhancing patient access across Australia.
  • Support for Educational Resources: This collaboration not only provides TGA-GMP certified products from Aurora but also offers educational resources for healthcare professionals, enhancing clinical knowledge and further professionalizing the medical cannabis industry.
  • Market Leadership Consolidation: By partnering with Leafio, Aurora aims to solidify its leadership position in the Australian market, leveraging Leafio's industry expertise and distribution network to improve patient treatment outcomes and satisfaction.
  • Industry Innovation Promotion: The partnership is expected to foster research and product innovation in the medical cannabis sector, potentially leading to better treatment results for patients while promoting sustainable development across the industry.
[object Object]
Preview
8.0
11-27TipRanks
Cannabis Stocks Surge as U.S. Medicare Weighs Coverage Options for TLRY, CGC, CRON

  • Medicare Coverage for CBD: U.S. Medicare is considering covering CBD treatments for certain patients, potentially boosting the cannabis industry as shares of leading companies rise by up to 4%.

  • Focus on Cancer and Palliative Care: The initiative primarily targets seniors undergoing cancer treatments or palliative care, marking a significant step for cannabis acceptance in medical settings.

  • Advocacy and Political Support: Payments financier Howard Kessler has engaged with Health and Human Services Secretary Robert F. Kennedy Jr. regarding expanded cannabis access, following previous support from President Trump.

  • Market Performance and Analyst Ratings: Cannabis stocks have struggled recently, with many trading as penny stocks; Tilray, for instance, has a Moderate Buy rating from analysts, suggesting a potential upside of over 92%.

[object Object]
Preview
9.5
11-18NASDAQ.COM
Tilray Brands Maintains Profit Growth with Impressive Q1 Performance

  • Tilray Brands' Profitability: Tilray Brands reported a net income of $1.5 million in Q1 fiscal 2026, a significant turnaround from a net loss of $34.7 million in the same quarter last year, driven by cost control and operational efficiency.

  • Verano's Revenue Challenges: Verano Holdings is experiencing revenue pressure due to a competitive U.S. market, with a 300 basis point contraction in gross margin to 47% in Q3 2025, despite a 13% reduction in SG&A expenses.

  • Aurora Cannabis Growth: Aurora Cannabis saw a 37% year-over-year increase in its medical cannabis segment sales, reaching nearly $65 million in Q1 fiscal 2026, supported by higher prices and improved production efficiencies.

  • Tilray's Stock Performance: Over the past six months, Tilray's shares have surged by 125.2%, significantly outperforming the industry, while currently trading at a forward Price-to-Sales ratio of 1.35X compared to the industry average of 3.16X.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Aurora Cannabis Inc (ACB) stock price today?

The current price of ACB is 4.57 USD — it has increased 0.66 % in the last trading day.

arrow icon

What is Aurora Cannabis Inc (ACB)'s business?

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company’s principal business lines are focused on the production, distribution and sale of cannabis and cannabis-derivative products in Canada and internationally. The Company’s segments include Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, IndiMed and CraftPlant. The Company also holds a 50.1% controlling interest in Bevo Farms Ltd., a supplier of propagated vegetables and ornamental plants in North America. Its subsidiaries include Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, Whistler Medical Marijuana Corporation, and Indica Industries Pty Ltd., among others.

arrow icon

What is the price predicton of ACB Stock?

Wall Street analysts forecast ACB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACB is 4.28 USD with a low forecast of 4.28 USD and a high forecast of 4.28 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Aurora Cannabis Inc (ACB)'s revenue for the last quarter?

Aurora Cannabis Inc revenue for the last quarter amounts to 90.37M USD, increased 11.40 % YoY.

arrow icon

What is Aurora Cannabis Inc (ACB)'s earnings per share (EPS) for the last quarter?

Aurora Cannabis Inc. EPS for the last quarter amounts to -0.91 USD, increased 313.64 % YoY.

arrow icon

What changes have occurred in the market's expectations for Aurora Cannabis Inc (ACB)'s fundamentals?

The market is revising Upward the revenue expectations for Aurora Cannabis Inc. (ACB) for FY2026, with the revenue forecasts being adjusted by 1.19% over the past three months. During the same period, the stock price has changed by -6.92%.
arrow icon

How many employees does Aurora Cannabis Inc (ACB). have?

Aurora Cannabis Inc (ACB) has 1101 emplpoyees as of December 05 2025.

arrow icon

What is Aurora Cannabis Inc (ACB) market cap?

Today ACB has the market capitalization of 259.14M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free